Insights from immuno-oncology

April 1, 2020

The hypoxia and profound inflammatory response associated with the pneumonitis observed with the SARS-CoV-2 virus responsible for the recent COVID-19 pandemic has overwhelmed intensive care facilities in the epicenters of infection including Wuhan, China, Northern Italy and in the USA, the Seattle and New York City areas. The Society for Immunotherapy of Cancer (SITC) stands along with and supports our colleagues in emergency departments, intensive care units (ICUs) and inpatient wards in the global effort to overcome this unprecedented pandemic. It is becoming apparent that the ‘ground glass’ infiltrative appearance seen on CT scans from patients with COVID-19 with pneumonitis is reminiscent of imaging from patients with immune checkpoint inhibitor (ICI)-induced pneumonitis.^{1 2} Additionally, elevated interleukin-6 (IL-6) is a hallmark inflammatory signature seen in serum of patients with severe COVID-19 acute respiratory distress.³ Many of us have experience with the administration of immune-modulatory agents, which is why the cancer immunotherapy community is poised to contribute to the current fight against COVID-19.

Read the full article here.

Welcome to your journey for creating a healthier you

Insights from immuno-oncology

Previous Article

Next Article

Insights from immuno-oncology

Previous Article

Next Article

Most Recent Articles

New research shows early intervention could slow the progression of COVID-19.

Patients with severe cases of COVID-19 were treated with Remdesivir for 5 and 10 days to determine efficacy of the duration of treatment.

Article featuring multiple Providence doctors published in the Journal for ImmunoTherapy of Cancer focused on immunological manipulations to lessen the severity of COVID-19.

How the clinical support team at Providence met an unprecedented challenge.

This report covers the first case of 2019-nCoV infection confirmed in the United States and describes the identification, diagnosis, clinical course, and management of the case.

This document identifies the potential risks of exposure to patients, allied health care staff, industry representatives and hospital administrators.

Gastrointestinal manifestations of COVID-19 are immediately reminiscent of previous coronavirus outbreaks and should raise concern about faecal shedding as a mode of transmission.

Described in this case series are the first 12 US patients confirmed to have COVID-19 from January 20 to February 5, 2020.

This study in the New England Journal of medicine examines clinical data from 24 COVID positive patients.